AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of relationship problems
Number of subjects: 34
Study 22546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater attachment anxiety among women
Number of subjects: 34
Study 22546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater attachment avoidance among women
Number of subjects: 34
Study 22546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater attachment anxiety among men
Number of subjects: 34
Study 21422390 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device implantation
Number of subjects: 50
Study 19861394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 18590256 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple point procedure
Number of subjects: 96
Study 18590256 — intervention group
Group type: COMPARATOR
Intervention: Single point procedure
Number of subjects: 96
Study 18590256 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removal with drills without cooling
Number of subjects: 96
Study 18590256 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removal with water spray cooled drills
Number of subjects: 96
Study 16091427 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients enrolled in clinical trials (139 patients)
Number of subjects: 274
Study 16091427 — intervention group
Group type: COMPARATOR
Intervention: Non-study patients (135 patients)
Number of subjects: 274
Study 16091427 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients who refused participation (28 patients)
Number of subjects: 274
Study 16091427 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients not recruited despite meeting inclusion criteria (17 patients)
Number of subjects: 274
Study 16091427 — intervention group
Group type: COMPARATOR
Intervention: Non-study patients treated with chemotherapy
Number of subjects: 274
Study 11815986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich chemotherapy (ifosfamide, etoposide, methotrexate, cisplatin, and cytosine arabinoside) followed by irradiation
Number of subjects: 52
Study 11815986 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy (lomustine, vincristine, and cisplatin) followed by irradiation
Number of subjects: 52
Study 10881087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine, 250 mg per day in a single dose for six days, repeated three weeks later.
Number of subjects: 20
Study 10881087 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (Glucantime), 20 mg/kg daily administered intravenously for 20 days.
Number of subjects: 20
Study 8825113 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheters (SC)
Number of subjects: 266
Study 8825113 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated catheters (UC)
Number of subjects: 266
Study 1799037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 0
Study 1799037 — intervention group
Group type: COMPARATOR
Intervention: Triiodinated agents
Number of subjects: 0
Study 7278216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling supine
Number of subjects: 32
Study 7278216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling sitting
Number of subjects: 32
Study 7278216 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate arm cranking standing
Number of subjects: 32
Study 7278216 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on a treadmill
Number of subjects: 32
Study 7278216 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping on a bench
Number of subjects: 32
Study 31120957 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR-901
Number of subjects: 28
Study 31120957 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 28
Study 31120957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29925490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir alafenamide (25 mg)
Number of subjects: 578
Study 29925490 — intervention group
Group type: COMPARATOR
Intervention: Boosted protease inhibitor regimen
Number of subjects: 578
Study 29925490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir group
Number of subjects: 578
Study 29925490 — intervention group
Group type: COMPARATOR
Intervention: Boosted protease inhibitor group
Number of subjects: 578
Study 26717109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochrome c levels in septic patients
Number of subjects: 77
Study 26717109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochrome c levels at enrollment
Number of subjects: 77
Study 26717109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochrome c levels over time
Number of subjects: 77
Study 24880443 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrina mulungu (500mg)
Number of subjects: 30
Study 24880443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500mg)
Number of subjects: 30
Study 22213436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (45%-55% VO(2peak), 30-60 minutes × 5 days/week; n = 12)
Number of subjects: 18
Study 22213436 — intervention group
Group type: COMPARATOR
Intervention: Observation (control; n = 6)
Number of subjects: 18
Study 22213436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 18
Study 20639802 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 1340
Study 20639802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1340
Study 17149725 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 2330 (tesofensine) 0.25 mg
Number of subjects: 261
Study 17149725 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 2330 (tesofensine) 0.5 mg
Number of subjects: 261
Study 17149725 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 2330 (tesofensine) 1.0 mg
Number of subjects: 261
Study 17149725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 15607043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Number of subjects: 16
Study 15607043 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Oxytocin
Number of subjects: 16
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders (computer or chart)
Number of subjects: 12
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal CME
Number of subjects: 12
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support systems/risk stratification
Number of subjects: 12
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational materials
Number of subjects: 12
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 12
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement projects
Number of subjects: 12
Study 12004636 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management aids in patient charts
Number of subjects: 12
Study 12004636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 9803773 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of Ginkgo biloba extract (EGb)
Number of subjects: 18
Study 9803773 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of tacrine
Number of subjects: 18
Study 7652633 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate (100 mg 3 times a day)
Number of subjects: 44
Study 7652633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg 3 times a day)
Number of subjects: 44
Study 7652633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2523646 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5, 5, 7.5, or 10 mg twice daily)
Number of subjects: 152
Study 2523646 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 or 100 mg once daily)
Number of subjects: 152
Study 2523646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isradipine and atenolol
Number of subjects: 152
Study 1064902 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly-disintegrating ferrous sulphate tablets
Number of subjects: 0
Study 1064902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous carbonate tablets
Number of subjects: 0
Study 1064902 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release ferrous sulphate tablets
Number of subjects: 0
Study 1064902 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate solution (reference)
Number of subjects: 0
Study 31594195 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurac technique
Number of subjects: 26
Study 31594195 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 26
Study 29364027 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT)
Number of subjects: 30
Study 29364027 — intervention group
Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 30
Study 26917439 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm implants (test group)
Number of subjects: 94
Study 26917439 — intervention group
Group type: COMPARATOR
Intervention: 10-mm implants (control group)
Number of subjects: 94
Study 25122617 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-delivered home-based physical activity program
Number of subjects: 307
Study 25122617 — intervention group
Group type: COMPARATOR
Intervention: Newspaper advertisements
Number of subjects: 307
Study 22569050 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nasal spray regimens (specific regimens not detailed)
Number of subjects: 60
Study 22569050 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SNOT scores
Number of subjects: 60
Study 22569050 — intervention group
Group type: EXPERIMENTAL
Intervention: Time post‐ESS
Number of subjects: 60
Study 22569050 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of an adherence risk factor
Number of subjects: 60
Study 22569050 — intervention group
Group type: COMPARATOR
Intervention: Age, gender, and nasal spray regimen
Number of subjects: 60
Study 20439954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi) with sulphadoxine‐pyrimethamine
Number of subjects: 600
Study 20439954 — intervention group
Group type: COMPARATOR
Intervention: Comparison areas (Control)
Number of subjects: 600
Study 20439954 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi (per protocol analysis)
Number of subjects: 600
Study 18561541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to vowel height changes
Number of subjects: 0
Study 18561541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to vowel backness changes
Number of subjects: 0
Study 18561541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to vowel roundedness changes
Number of subjects: 0
Study 16029223 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy with a Macintosh laryngoscope
Number of subjects: 40
Study 16029223 — intervention group
Group type: COMPARATOR
Intervention: Lingual traction with jaw thrust
Number of subjects: 40
Study 12590903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogenic shock patients
Number of subjects: 6676
Study 12590903 — intervention group
Group type: EXPERIMENTAL
Intervention: Early shock development (days 1-2)
Number of subjects: 6676
Study 12590903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate or late shock development (>80%)
Number of subjects: 6676
Study 12590903 — intervention group
Group type: COMPARATOR
Intervention: Non-shock patients
Number of subjects: 6676
Study 12590903 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day survivors with cardiogenic shock
Number of subjects: 6676
Study 10850381 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (r-metHuG-CSF)
Number of subjects: 0
Study 10850381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8947979 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 60 mg/day
Number of subjects: 12
Study 8947979 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg/day
Number of subjects: 12
Study 8947979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1901782 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 9
Study 1901782 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 9
Study 1901782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7006425 — intervention group
Group type: EXPERIMENTAL
Intervention: EEA stapler
Number of subjects: 0
Study 7006425 — intervention group
Group type: COMPARATOR
Intervention: Traditional hand-sewn technique
Number of subjects: 0
Study 30624403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue reduction technique (split skin graft or linear incision)
Number of subjects: 263
Study 30624403 — intervention group
Group type: COMPARATOR
Intervention: Tissue preservation technique
Number of subjects: 263
Study 30027912 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5% solution plus low-level light therapy twice per day
Number of subjects: 50
Study 30027912 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil 5% solution with a laser comb system turned off (placebo)
Number of subjects: 50
Study 30027912 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5% solution plus low-level light therapy
Number of subjects: 50
Study 26468161 — intervention group
Group type: EXPERIMENTAL
Intervention: Haem arginate
Number of subjects: 14
Study 26468161 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (l-arginine)
Number of subjects: 14
Study 25343263 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 104
Study 23095424 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 56
Study 19953262 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback gain of 0.5-4 pixels/N
Number of subjects: 14
Study 19953262 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback gain of 64-1,424 pixels/N
Number of subjects: 14
Study 19953262 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback gain increase
Number of subjects: 14
Study 17940103 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity, individualized treadmill training
Number of subjects: 30
Study 17940103 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity, generalized treadmill training
Number of subjects: 30
Study 16088848 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg, increased to 32 mg after one month)
Number of subjects: 5231
Study 12419426 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional or accelerated radiotherapy (RT) with or without concomitant carboplatin
Number of subjects: 243
Study 12419426 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin, etoposide, and RT
Number of subjects: 243
Study 12419426 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant carboplatin, 5-fluorouracil, and RT
Number of subjects: 243
Study 12419426 — intervention group
Group type: EXPERIMENTAL
Intervention: T stage (T1, T2, T3, T4)
Number of subjects: 243
Study 12419426 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactor analysis using Cox proportional hazards regression analysis
Number of subjects: 243
Study 11273369 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Reasoning Exercise (CRE) scored by tutors
Number of subjects: 102
Study 11273369 — intervention group
Group type: COMPARATOR
Intervention: Crossover tutor's ratings
Number of subjects: 102
Study 11273369 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE
Number of subjects: 102
Study 9745827 — intervention group
Group type: EXPERIMENTAL
Intervention: Baerveldt glaucoma implant
Number of subjects: 22
Study 10122606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home care
Number of subjects: 0
Study 10122606 — intervention group
Group type: COMPARATOR
Intervention: Geriatric ward care
Number of subjects: 0
Study 3311145 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing without chewing
Number of subjects: 24
Study 3311145 — intervention group
Group type: COMPARATOR
Intervention: Chewing food
Number of subjects: 24
Study 3311145 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of viscous polysaccharides or 'slow-release' carbohydrates
Number of subjects: 24
Study 29652929 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA vaccine (Groups 1-3)
Number of subjects: 4005
Study 29652929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 4)
Number of subjects: 4005
Study 27743130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented garlic extract (FGE), 2 sachets/day for 12 weeks
Number of subjects: 75
Study 27743130 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 sachets/day for 12 weeks
Number of subjects: 75
Study 25613811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 200
Study 25613811 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost-timolol fixed combination (LTFC)
Number of subjects: 200
Study 23941362 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglucidic low‐calorie diet (NGLCD)
Number of subjects: 120
Study 23941362 — intervention group
Group type: COMPARATOR
Intervention: Low‐fat diet (LFD)
Number of subjects: 120
Study 23941362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (NGLCD and LFD)
Number of subjects: 120
Study 21906390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (HFCWO)
Number of subjects: 52
Study 21906390 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 52
Study 18196414 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished stems (165 hips)
Number of subjects: 395
Study 18196414 — intervention group
Group type: EXPERIMENTAL
Intervention: Satin stems (123 hips)
Number of subjects: 395
Study 18196414 — intervention group
Group type: EXPERIMENTAL
Intervention: Matte stems (145 hips)
Number of subjects: 395
Study 17015818 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5-300 mg/d)
Number of subjects: 329
Study 17015818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 17015818 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 329
Study 14692709 — intervention group
Group type: EXPERIMENTAL
Intervention: Liverman capsule
Number of subjects: 24
Study 14692709 — intervention group
Group type: COMPARATOR
Intervention: Legalon capsule
Number of subjects: 24
Study 14692709 — intervention group
Group type: COMPARATOR
Intervention: Silymarin tablet
Number of subjects: 24
Study 11053332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity endurance training
Number of subjects: 0
Study 11053332 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity endurance training
Number of subjects: 0
Study 11053332 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8922657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) 20 micrograms three times daily for 7 days
Number of subjects: 29
Study 8922657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) stimulation
Number of subjects: 29
Study 1372418 — intervention group
Group type: EXPERIMENTAL
Intervention: AC pacemaker (accelerometer-based)
Number of subjects: 20
Study 1372418 — intervention group
Group type: COMPARATOR
Intervention: PZ pacemaker (piezoelectric crystal)
Number of subjects: 20
Study 1372418 — intervention group
Group type: COMPARATOR
Intervention: Intrinsic HR
Number of subjects: 20
Study 1372418 — intervention group
Group type: EXPERIMENTAL
Intervention: AC pacemaker (during bicycle ergometry)
Number of subjects: 20
Study 1372418 — intervention group
Group type: COMPARATOR
Intervention: PZ pacemaker (during bicycle ergometry)
Number of subjects: 20
Study 1372418 — intervention group
Group type: EXPERIMENTAL
Intervention: AC pacemaker (during stair climbing)
Number of subjects: 20
Study 1372418 — intervention group
Group type: COMPARATOR
Intervention: PZ pacemaker (during stair climbing)
Number of subjects: 20
Study 31308348 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet
Number of subjects: 0
Study 31308348 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 0
Study 27889937 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in the home
Number of subjects: 1491
Study 27889937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing a latrine with one other household
Number of subjects: 1491
Study 27889937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing a latrine with more than one household
Number of subjects: 1491
Study 26481870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance movement based intervention
Number of subjects: 201
Study 26481870 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching and exercise intervention
Number of subjects: 201
Study 26481870 — intervention group
Group type: COMPARATOR
Intervention: No intervention waitlist-control group
Number of subjects: 201
Study 26481870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 201
Study 23391367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of arbidol (0.2 g, 0.4 g, 0.8 g)
Number of subjects: 12
Study 23391367 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of arbidol (0.2 g, 3 times a day for 7 days)
Number of subjects: 12
Study 21853611 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24
Study 21853611 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 24
Study 19734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural family management for 18 mothers
Number of subjects: 55
Study 19734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation for 19 mothers
Number of subjects: 55
Study 19734180 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 18 mothers
Number of subjects: 55
Study 17439903 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mug of subcutaneously injected interferon beta 1a (IFNp‐1 a)
Number of subjects: 62
Study 17439903 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 mug of subcutaneously injected interferon beta 1a (IFNp‐1 a)
Number of subjects: 62